5 products found
Adiso Therapeutics Products
-
Single Strain Live Biotherapeutic Product (SS-LBP) Platform
-
Adiso - Model ADS024 - Prevention of CDI Recurrence
ADS024 is an oral single strain live biotherapeutic product (SS-LBP). A naturally occurring live biotherapeutic product, ADS024 possesses a dual mechanism of action. It is bactericidal toward Clostridioides difficile and degrades Toxins A and B produced by C. difficile while maintaining other components of the microbiome. ADS024 is a single strain multimodal LBP and is manufactured from a pure, clonal bacterial cell bank, ...
-
Adiso - Model ADS024 - Ulcerative Colitis
ADS024 is an oral single strain live biotherapeutic product (SS-LBP). A naturally occurring live biotherapeutic product, ADS024 modulates inflammation as a single strain multimodal LBP and has been shown to reduce neutrophil trafficking through the colonic epithelium. ADS024 is manufactured from a pure, clonal bacterial cell bank, yielding a standardized lyophilized drug product eliminating the need to directly source from donor fecal ...
-
Adiso - Model ADS00X - Neuroinflammation
ADS00X has demonstrated pre-clinical efficacy in 3 models of neuroinflammatory disease. Adiso is pursuing confirmatory evidence which supports the impact of our SS-LBP products on the Gut-Brain ...
-
Small Molecule Platform
-
Adiso - Model ADS051 - Ulcerative Colitis
ADS051 is an oral, gut-restricted, small molecule modulator of neutrophil trafficking and activation for the treatment of ulcerative colitis. ADS051 blocks MRP2 release of HXA3 gradient, while also blocking FPR1 activation of neutrophils within the colonic epithelium. Unlike currently available therapies, this addresses neutrophil-mediated tissue damage, a hallmark of UC pathology. In a healthy volunteer study, ADS051 was safe and well-tolerated and ...
-
Model ADS032 - Respiratory Inflammation
ADS032 is a novel small molecule inhibitor that locally blocks two types of inflammasomes simultaneously, NLRP1 and NLRP3 – the innate immune system’s receptors and first line sensors of pathogens and other danger signals. Chronic activation of NLRP1 and NLPR3 is directly implicated in a wide range of inflammation-triggered conditions across multiple organ systems. By targeting both NLRP3 and NLRP1, ADS032 may provide a comprehensive ...